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AbstrAct
Di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT) demonstrates 
potent anti-cancer activity. We previously demonstrated that 14C-Dp44mT enters and 
targets cells through a carrier/receptor-mediated uptake process. Despite structural 
similarity, 2-benzoylpyridine 4-ethyl-3-thiosemicarbazone (Bp4eT) and pyridoxal 
isonicotinoyl hydrazone (PIH) enter cells via passive diffusion. Considering albumin 
alters the uptake of many drugs, we examined the effect of human serum albumin 
(HSA) on the cellular uptake of Dp44mT, Bp4eT and PIH. Chelator-HSA binding 
studies demonstrated the following order of relative affinity: Bp4eT≈PIH>Dp44mT. 
Interestingly, HSA decreased Bp4eT and PIH uptake, potentially due to its high 
affinity for the ligands. In contrast, HSA markedly stimulated Dp44mT uptake by 
cells, with two saturable uptake mechanisms identified. The first mechanism saturated 
at 5-10 µM (Bmax:1.20±0.04 × 107 molecules/cell; Kd:33±3 µM) and was consistent 
with a previously identified Dp44mT receptor/carrier. The second mechanism was 
of lower affinity, but higher capacity (Bmax:2.90±0.12 × 107 molecules/cell; Kd:65±6 
µM), becoming saturated at 100 µM and was only evident in the presence of HSA. 
This second saturable Dp44mT uptake process was inhibited by excess HSA and had 
characteristics suggesting it was mediated by a specific binding site. Significantly, 
the HSA-mediated increase in the targeting of Dp44mT to cancer cells potentiated 
apoptosis and could be important for enhancing efficacy.
INtrODUctION
Various exogenous compounds, including drugs 
such as warfarin [1], chlorpromazine [2], digitoxin [2] 
and ibuprofen [2], as well as endogenous molecules, 
such as fatty acids [3], steroids [4, 5] and inorganic ions 
[5, 6], bind extensively to albumin. In general, drug-
protein interactions can adversely affect drug delivery by 
decreasing free drug levels available to traverse the plasma 
membrane to reach intracellular targets [7-9]. 
Conversely, albumin has also been demonstrated to 
aid the uptake and targeting of albumin-bound molecules, 
including fatty acids [5, 10, 11]. Studies have suggested 
that, upon binding to the cell membrane, albumin 
undergoes a conformational change, which subsequently 
results in the release of albumin-bound fatty acids [5, 
11]. The release of the fatty acids in the vicinity of the 
membrane potentiates the delivery of these molecules to 
their receptor for cellular uptake [5, 11]. The subsequent 
reduced affinity of albumin for the cell surface then allows 
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its release from the membrane [5, 11]. This mechanism 
has also been described for the cellular uptake of other 
albumin-bound molecules, such as testosterone and 
tryptophan, demonstrating the biological importance 
of albumin in the transport and delivery of a variety of 
ligands [5, 12-14].
Interestingly, albumin has been observed to 
accumulate within the interstitium of solid tumors [15-17]. 
This occurs due to the highly permeable tumor vasculature 
and the insufficient lymphatic drainage present in tumor 
tissue [15-17]. This characteristic is specifically known as 
the “enhanced permeability and retention effect” [15-17]. 
Thiosemicarbazone ligands are anti-cancer agents 
that bind metal ions and have shown anti-tumor activity 
in numerous investigations in vitro and in vivo, including 
many clinical trials [18-22]. As part of a specific strategy 
to generate selective and active anti-tumor agents, the di-
2-pyridylketone thiosemicarbazones were developed [18, 
19, 23-25]. In particular, the ligand, di-2-pyridylketone 
4,4-dimethyl-3-thiosemicarbazone (Dp44mT; Fig. 1A) 
and its analogs, were shown to have potent in vitro and in 
vivo anti-tumor activity [18, 24-26] and to possess marked 
anti-metastatic efficacy [27-29]. Additionally, the activity 
of Dp44mT was potentiated in drug-resistant cancer cells 
[24].
In terms of its mechanism of action, Dp44mT 
accumulates within lysosomes, where it forms redox-
active metal complexes [23, 25, 30] that mediate 
lysosomal membrane permeabilization to induce apoptosis 
[31]. Other modes of action include inhibition of the 
rate-limiting step of DNA synthesis that is catalyzed by 
ribonucleotide reductase [32] and up-regulation of N-myc 
downstream regulated gene 1 [33], resulting in inhibition 
of proliferation and metastasis, respectively [24, 26, 27]. 
Interestingly, it has been recently demonstrated 
that Dp44mT binds to a saturable receptor/carrier on 
a variety of cell-types [34]. Other structurally-related 
thiosemicarbazones, such as 2-benzoylpyridine 4-ethyl-3-
thiosemicarbazone (Bp4eT; Fig. 1A), or aroylhydrazones 
(e.g., pyridoxal isonicotinoyl hydrazone, PIH; Fig. 1A), 
entered cells via a non-saturable mechanism consistent 
with passive diffusion [34, 35]. The role of this receptor/
carrier in targeting Dp44mT to cancer cells could be 
important for explaining the marked anti-tumor and anti-
metastatic activity, which markedly surpasses other similar 
agents [18, 24-29].
Considering the increased distribution of albumin 
in the tumor interstitium and the crucial role of this 
protein as a drug shuttle [36], it was critical to evaluate 
the interaction between Dp44mT and albumin. In order 
to understand the importance of key structural features 
of Dp44mT in its uptake, studies were performed in 
comparison to the related ligands, Bp4eT and PIH (Fig. 
1A), which possess high and low anti-proliferative 
activity, respectively [37, 38].
Herein, for the first time, we describe a novel 
mechanism involved in the cellular uptake and targeting 
of Dp44mT that is markedly facilitated by human serum 
albumin (HSA). Intriguingly, this process is distinct 
from Dp44mT’s structurally similar analogs, Bp4eT 
and PIH, whose cellular uptake was inhibited by HSA. 
Two saturable mechanisms of Dp44mT uptake by cells 
were identified. The first uptake mechanism saturated at 
5-10 µM, and this observation was consistent with the 
previously identified Dp44mT receptor/carrier [34]. In 
contrast, the second mechanism of Dp44mT uptake was 
a low affinity, high capacity process which saturated at 
>100 µM and was only evident in the presence of HSA. 
The enhanced uptake of Dp44mT by HSA was identified 
in multiple neoplastic cell-types and a normal cell-type. 
Moreover, the HSA-mediated increase in Dp44mT uptake 
was specific for this protein and was inhibited by excess 
HSA. The enhanced cellular targeting of Dp44mT by HSA 
potentiated the anti-proliferative and apoptotic effects of 
the agent, facilitating its anti-tumor efficacy.
rEsULts
Fluorescence Quenching of HsA by chelators 
Indicates Direct Ligand-binding
Fluorescence spectroscopy was initially used to 
examine the ability of the ligands to bind HSA (Fig. 1Bi-
iii). It is well known that HSA contains a single tryptophan 
(Trp-214) situated in sub-domain IIA that fluoresces upon 
excitation at 295 nm [39, 40]. The conformational state of 
HSA can influence the exposure of this tryptophan residue, 
and thereby affect tryptophan fluorescence [39].
HSA alone had a pronounced fluorescence 
maximum at 345 nm (Fig. 1Bi-iii), due to Trp-214 [5]. 
No minimal intrinsic fluorescence was demonstrated for 
Dp44mT, Bp4eT, or PBS alone (Fig. 1Bi, ii). In contrast, 
some intrinsic fluorescence was observed for PIH (Fig. 
1Biii). The fluorescence intensity of HSA decreased with 
increasing concentrations of all the ligands (i.e., A→L; 
0-3.67 µM chelator concentrations; see Fig. 1Bi-iii), 
indicating the interaction of these agents with HSA.
circular Dichroism (cD) spectroscopy 
Demonstrated No secondary conformational 
Alteration in HsA after Incubation with Dp44mt, 
bp4et or PIH
To determine whether the ligands induce a change 
in the protein conformation of HSA, changes in protein 
secondary structure after incubation with Dp44mT, 
Bp4eT, or PIH, were examined using CD spectroscopy 
(Fig. 1Ci-iii). The CD spectrum of HSA exhibited two 
negative peaks at 208 and 222 nm that are characteristic 
Oncotarget10376www.impactjournals.com/oncotarget
table 1: the effect of the ligands, Dp44mt, bp4et or PIH, or the chaotropic 
agent, guanidine hydrochloride (GndCl), on α-helix and β-sheet content of HSA.
% α-Helix % β-Sheets
HSA 67.73% 5.91%
HSA + Dp44mT 67.84% 5.89%
HSA + Bp4eT 66.86% 6.02%
HSA + PIH 67.17% 5.82%
HSA + GndCl* 1.79% 34.84%
*Note: GndCl is used as a positive control to induce alterations in HSA secondary 
structure.
Figure 1: (A): Line drawings of the chemical structures of the iron chelators: di-2-pyridylketone 4,4-dimethyl-3-
thiosemicarbazone (Dp44mT), 2-benzoylpyridine 4-ethyl-3-thiosemicarbazone (Bp4eT) and pyridoxal isonicotinoyl 
hydrazone (PIH). Asterisk (*) indicates position of the 14C-label. (B) Fluorescence emission spectrum of HSA (2 µM) excited at 295 nm 
in the presence of increasing concentrations (A→L; 0-3.67 µM) of: (i) Dp44mT; (ii) Bp4eT; or (iii) PIH in PBS at 37oC/pH 7.4. (C) Circular 
dichroism of HSA (2 µM) in the presence of: (i) Dp44mT, (ii) Bp4eT or (iii) PIH (10 µM) after a 2 h incubation at 37oC. Results shown are 
typical of 3 experiments performed.
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of its predominantly α-helical structure (Fig. 1Ci-iii) 
[41]. In fact, analysis of the secondary structure revealed 
67.73% α-helices (Table 1), which is in agreement with 
the X-ray crystal structure of HSA [42]. Importantly, no 
marked alterations in secondary structure were detected 
after incubation with these ligands (Fig. 1Ci-iii), resulting 
in similar levels of α-helical secondary structure content 
(66.86 – 67.84%; Table 1). Interestingly, minimal levels 
of β-sheet content (5.91%; Table 1) were detected and 
were not appreciably altered in the presence of the 
chelators (5.82-6.02%; Table 1). As previously observed 
[43], the chaotrope and positive control for protein 
folding, guanidine hydrochloride (GndCl), resulted in the 
denaturation of HSA (Fig. 1Ci-iii), as demonstrated by a 
decrease in α-helix content to 1.79%, and the simultaneous 
increase in β-sheet content to 34.84% (Table 1). 
Collectively, these results suggest the ligands, Dp44mT, 
Bp4eT and PIH, do not mediate significant changes in the 
secondary structure of HSA upon binding.
14c-bp4et and 14c-PIH bind to HsA More Avidly 
than 14c-Dp44mt
Further studies were then performed to characterize 
the binding of the ligands to HSA using the equilibrium 
dialysis technique [44]. In these experiments, a 
physiologically-relevant concentration of HSA in the 
Figure 2: Equilibrium dialysis studies demonstrating the binding of Dp44mt, bp4et or PIH to albumin. In these studies, 
HSA or BSA (40 mg/mL) was pre-incubated with the 14C-chelators (25 µM) for 2 h/37oC and placed into dialysis sacs and the release of 
the 14C-chelators from the dialysis sac into the dialysate was then examined after a 24 h/4oC equilibration period. For competition studies: 
(A) HSA (40 mg/mL) was pre-incubated for 2 h/37oC with a 200-fold excess of unlabeled warfarin or ibuprofen (5 mM), or (B) a 20-fold 
excess of unlabeled Dp44mT, Bp4eT or PIH (0.5 mM). Results are expressed as mean ± S.E.M. of at least 3 experiments.
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plasma (40 mg/mL; [41, 45]) was pre-incubated with 
the 14C-chelators (25 µM) for 2 h/37oC to duplicate 
the incubation period used in subsequent experiments 
examining uptake of the 14C-ligands by cells. BSA (40 
mg/mL) was chosen as a control protein since it possesses 
75.6% sequence identity with HSA [5]. These solutions 
were then placed into dialysis sacs and the release of the 
14C-chelators from the sac into the dialysate was then 
examined after 24 h/4oC to ensure equilibrium (Fig. 2A). 
In the absence of protein (i.e., see “control” in 
Fig. 2A), dialysis of 14C-ligands was performed against 
the buffer-only control and led to the release of ≈ 50% 
of each of the 14C-ligands from the dialysis sac into the 
dialysate (Fig. 2A). This observation demonstrated 
that the incubation period was sufficient to establish 
the equilibrium of these low molecular weight ligands 
between the dialysis sac and dialysate. 
The presence of HSA inside the dialysis sac 
resulted in a marked and significant (p<0.001) decrease 
in the release of 14C-Dp44mT, 14C-Bp4eT and 14C-PIH 
into the dialysate to 22.0 ± 1.0%, 4.0 ± 0.3% and 6.0 
± 0.3%, respectively, compared to the relative control 
(i.e., control sacs without HSA; Fig. 2A). These results 
demonstrated that the 14C-ligands were directly binding 
to HSA and being retained in the dialysis sac. Clearly, 
HSA retained the 14C-labeled ligands to different extents, 
with 14C-Dp44mT binding significantly (p<0.001) less 
avidly than either 14C-Bp4eT or 14C-PIH, which bound to 
HSA with approximately similar avidity (Fig. 2A). These 
findings indicate the relative binding affinity of the ligands 
for HSA to be in the following order: 14C-Bp4eT ≈ 14C-PIH 
> 14C-Dp44mT (Fig. 2A). 
Moreover, BSA (40 mg/mL) also significantly 
(p<0.001) decreased the percentage of 14C-Dp44mT, 
14C-Bp4eT and 14C-PIH released from the sac to 21 ± 
0.5%, 9 ± 0.3% and 39 ± 0.3%, respectively, compared 
to control (i.e., control sacs without protein; Fig. 2A). 
Further, no significant difference (p>0.05) in the binding 
of Dp44mT to either HSA or BSA was evident (Fig. 2A). 
These data also demonstrate that Bp4eT and PIH bind 
BSA significantly (p<0.001) less avidly relative to HSA.
Considering the HSA-binding described above, 
we next examined if the 14C-ligands (25 µM) bind to the 
classical drug-binding sites of HSA, namely, Sudlow’s 
site I and/or site II [5]. In these studies, a standard 
competition protocol was used, whereby HSA (40 mg/
mL) was pre-incubated for 2 h/37oC with a 200-fold 
excess of unlabeled warfarin or ibuprofen (5 mM; Fig. 2A) 
that bind to Sudlow’s sites I or II, respectively [5]. The 
14C-chelators (25 µM) were then added and the samples 
further incubated for 2 h/37oC, followed by a 24 h/4oC 
dialysis period. As a control, in the absence of HSA, 
equilibrium dialysis of the 14C-ligands for 24 h/4oC was 
also performed in the presence of an excess of unlabeled 
ibuprofen or warfarin. 
Irrespective of the excess warfarin or ibuprofen, the 
distribution of the 14C-ligands reached equilibrium (i.e., 
the 14C-ligand reached ≈50% in both the dialysis sac and 
dialysate) in the absence of HSA (Fig. 2A). In the presence 
of ibuprofen or warfarin and HSA, no significant (p>0.05) 
alteration in 14C-Dp44mT release from the dialysis sac 
occurred when compared to 14C-Dp44mT and HSA alone 
(Fig. 2A). These findings suggest that Dp44mT does 
not compete effectively with warfarin or ibuprofen at 
Sudlow’s site I and II, respectively. Incubating HSA with a 
molar excess of warfarin, but not ibuprofen, led to a slight, 
albeit significant (p<0.01) increase in 14C-Bp4eT release 
from the dialysis sac when compared to HSA alone (Fig. 
2A). This observation suggests that 14C-Bp4eT binds to 
a limited extent to Sudlow’s site I, or in the vicinity of 
this site. More importantly, 14C-PIH release from the HSA-
containing dialysis sac was markedly and significantly 
(p<0.001) increased in the presence of an excess of 
warfarin or ibuprofen, relative to the incubation of 14C-PIH 
with HSA alone (Fig. 2A). 
Overall, these data suggest: (1) PIH either directly 
competes with warfarin and ibuprofen for Sudlow’s sites 
I and II, respectively, or that PIH binds HSA at other 
sites that are allosterically modulated by warfarin- or 
ibuprofen-binding to HSA; (2) Bp4eT sparingly competes 
with warfarin at Sudlow’s site I only; and (3) Dp44mT 
does not significantly (p>0.05) compete with warfarin or 
ibuprofen.
Competition Experiments Reveal HSA has 
common and/or Interacting binding sites for the 
Ligands
Competition experiments using equilibrium dialysis 
were also used to evaluate if the three 14C-ligands became 
bound to a common, or different, site on HSA. Binding 
of 14C-Dp44mT, 14C-Bp4eT, or 14C-PIH (25 µM) to HSA 
was examined in competition with a 20-fold excess (0.5 
mM) of the relevant unlabeled competitor ligand, namely 
Dp44mT, Bp4eT or PIH, which was pre-incubated with 
HSA for 2 h/37oC prior to adding the 14C-ligand (Fig. 
2B). The unlabeled chelator could only be used at a 20-
fold excess relative to the 14C-ligand due to their limited 
solubility. The solutions were then placed into dialysis 
sacs and the release of 14C-ligands from the dialysis sac 
into the dialysate examined after 24 h/4oC.
Incubation of HSA with an excess of unlabeled 
Bp4eT induced a slight, but significantly (p<0.05) 
increased release of 14C-Dp44mT from the dialysis sac 
relative to that found in the absence of this unlabeled 
ligand (Fig. 2B). This observation suggested competition 
between unlabeled Bp4eT and 14C-Dp44mT for a common 
HSA-binding region (Fig. 2B). However, no significant 
(p>0.05) change in the release of the 14C-label into the 
dialysate was evident when an excess of unlabeled PIH 
was incubated with 14C-Dp44mT and HSA relative to 
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that found when 14C-Dp44mT and HSA were incubated 
together (Fig. 2B). Incubation of HSA with unlabeled 
Dp44mT or PIH had no significant effect on 14C-Bp4eT 
release from HSA (Fig. 2B). However, incubating 
HSA with an excess of unlabeled Dp44mT or Bp4eT 
significantly (p<0.001-0.05) increased the release of 
14C-PIH from the HSA-containing dialysis sac relative to 
that found with HSA alone (Fig. 2B). This latter finding 
suggests these drugs possess common binding sites 
and inhibit PIH from binding to HSA, or alternatively, 
Dp44mT and Bp4eT bind at distant sites which may then 
allosterically influence 14C-PIH-binding. In conclusion, 
competition experiments revealed that HSA has some 
common and/or interacting sites for these ligands.
computational Docking studies
Molecular docking studies were then performed 
to further characterize the ligand-binding sites on HSA 
(Supplementary Fig. 1A-B). Warfarin (Supplementary 
Fig. 1Ai) and ibuprofen (Supplementary Fig. 1Bi) were 
also docked and complexed to HSA as relevant controls, 
considering that their binding to Sudlow’s site I and II, 
respectively, are well established [5]. The best docking 
poses of warfarin and ibuprofen correctly reproduced the 
experimental bioactive conformations with a root mean 
squared deviation of less than 1 Å from that of the ligand 
pose present in the X-ray structure (PDB code: 2BXD and 
2BXG, respectively).
Docking at sudlow’s site I of HsA
These simulations docked warfarin, Dp44mT, 
Bp4eT and PIH at Sudlow’s site I of HSA (Supplementary 
Fig. 1Ai-iv). Both warfarin and PIH made H-bonds with 
HSA (Supplementary Fig. 1Ai, iv), whereas Dp44mT 
and Bp4eT predominantly made hydrophobic and van 
der Waals interactions (Supplementary Fig. 1Aii-iii). 
The phenyl ring of warfarin resulted in π–π stacking with 
Phe211 and Trp214 and cation-π interactions with Lys199, 
which underlie its high binding affinity (Supplementary 
Fig. 1Ai). The docking of PIH (Supplementary Fig. 
1Aiv) showed H-bonds with Tyr150, Arg222, Arg257 
and Ala291. The hydrophobic groups of Dp44mT 
(Supplementary Fig. 1Aii) and Bp4eT (Supplementary 
Fig. 1Aiii) were favorably enclosed by the hydrophobic 
regions on HSA. Interestingly, the orientation of Bp4eT 
was flipped compared to Dp44mT when docked into 
Sudlow’s site I, despite these two ligands having similar 
structures (Fig. 1A). This effect may due to the formation 
of a minimum energy conformation by Bp4eT under this 
pose [46].
As an approximation of the interaction of the ligand 
with the protein in terms of relative binding affinity, 
the GlideScore or GScore (GS; or docking score) was 
calculated from the docking simulations [46]. Docking of 
the agents at Sudlow’s site I demonstrated the following 
GS order: warfarin (GS = -8.40 kcal/mol) > Bp4eT (GS = 
-8.15 kcal/mol) > PIH (GS = -8.03 kcal/mol) > Dp44mT 
(GS = -7.21 kcal/mol). These data suggest Dp44mT has 
the least affinity for Sudlow’s site I. However, the GS 
indicates that Bp4eT and PIH have a similar affinity for 
Sudlow’s site I. Notably, the GS parameter is an estimate 
only, and as the GS values are similar for Bp4eT and PIH, 
it should not be used to rank these ligands in terms of 
relative binding affinity. 
Docking at sudlow’s site II of HsA
Ibuprofen, Dp44mT, Bp4eT and PIH were 
also virtually docked at Sudlow’s site II of HSA 
(Supplementary Fig. 1Bi-iv). In the X-ray structure of 
HSA and ibuprofen [47], ibuprofen interacts with Arg410, 
Tyr411 and Lys414 via H-bonds. These interactions were 
correctly modeled with an additional cation-π interaction 
between Arg410 and the phenyl ring of ibuprofen 
(Supplementary Fig. 1Bi). PIH formed H-bonds to Arg410 
(2.07 Å) and Tyr411 (2.18 Å) through its hydroxymethyl 
and hydroxyl groups, respectively (Supplementary Fig. 
1Biv). The distal parts of the molecule were mainly 
located in a hydrophobic pocket, in a similar fashion to 
that of ibuprofen (cf. Supplementary Fig. 1Bi to 1Biv). 
Interestingly, while Dp44mT and Bp4eT both bind in the 
same putative binding pocket as PIH, a different ligand 
orientation was observed. The main interactions were 
H-bonds formed from the pyridyl nitrogen acceptor to 
Asn391 and cation-π interactions of the second pyridyl 
ring with Lys414 (Supplementary Fig. 1Bii-iii). 
The GS obtained after docking the ligands at 
Sudlow’s site II demonstrated the following order, namely: 
ibuprofen (GS = -8.50 kcal/mol) > PIH (GS = -6.0 kcal/
mol) > Bp4eT (GS = -5.0 kcal/mol) > Dp44mT (GS = -4.9 
kcal/mol). Again, Dp44mT showed the lowest interaction 
with Sudlow’s site II, which was consistent with the lack 
of effect of this ligand in competition studies performed 
using equilibrium dialysis experiments (Fig. 2A). On the 
other hand, PIH showed the highest affinity for Sudlow’s 
site II, relative to Bp4eT and Dp44mT, which was 
consistent with the dialysis studies assessing competition 
with ibuprofen (Fig. 2A).
In conclusion, molecular modeling indicated that 
14C-PIH binds to HSA at both Sudlow’s site I and II, 
potentially via H-bonds and this was consistent with the 
competition studies with warfarin and ibuprofen in dialysis 
experiments (Fig. 2A). Molecular modeling suggested that 
14C-Bp4eT may share these HSA-binding sites, although 
in dialysis studies (Fig. 2A), limited competition was 
observed with warfarin only, presumably at Sudlow’s site 
I. Dp44mT had the weakest interaction with Sudlow’s 
site I and II, which was in agreement with its lack of 
effect in competition studies with warfarin and ibuprofen, 
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respectively (Fig. 2A).
HsA Markedly Increases 14c-Dp44mt Uptake, 
but Decreases 14c-bp4et and 14c-PIH Uptake
Considering that: (1) these ligands bind to albumin 
(Fig. 1B, 2A-B, Supplementary Fig. 1A-B); (2) the high 
levels of protein accumulation in the tumor interstitium 
due to the enhanced permeability and retention effect [15-
17]; and (3) the potential influence of protein-drug binding 
on drug bioavailability [7], we examined the cellular 
targeting and uptake of 14C-Dp44mT, 14C-Bp4eT and 
14C-PIH in the presence and absence of the serum proteins, 
HSA, BSA or Tf (Fig. 3A-C). 
In these studies, concentrations of apo-Tf and HSA 
at 5 mg/mL and 40 mg/mL, respectively, were used to 
approximate their physiological concentrations in human 
plasma [5, 48]. 14C-Ligand uptake was also assessed 
relative to Tf at 40 mg/mL, as a direct comparison to 
HSA at this concentration. Similarly, HSA was used at 5 
mg/mL as a comparison to physiological Tf levels (52). 
To examine species-specific differences in terms of the 
14C-ligand interaction with albumin, BSA (40 mg/mL) was 
chosen as a control protein due to its homology with HSA 
[5]. Studies were initially performed using SK-N-MC cells 
that have been well characterized in terms of the uptake 
and biological activity of these ligands [24, 35, 37, 38].
Interestingly, 14C-Dp44mT uptake was significantly 
(p<0.001-0.05) increased in the presence of HSA (5 mg/
mL and 40 mg/mL) relative to the control (i.e., ligand 
alone in control media) at all time points examined (Fig. 
3A). In contrast, addition of Tf (5 or 40 mg/mL) or BSA 
(40 mg/mL) led to no significant (p>0.05) alteration in 
14C-Dp44mT uptake relative to the control (i.e., protein-
free media) after a 15-120 min incubation (Fig. 3A). 
In contrast to the observations with 14C-Dp44mT, 
HSA (5 or 40 mg/mL), Tf (40 mg/mL), or BSA (40 mg/
mL), markedly and significantly (p<0.001-0.05) reduced 
14C-Bp4eT uptake by cells relative to the control (i.e., 
ligand alone) at all time points (Fig. 3B). On the other 
hand, Tf at 5 mg/mL had no significant (p>0.05) effect 
on 14C-Bp4eT uptake (Fig. 3B). As observed for Bp4eT, 
14C-PIH uptake was also significantly (p<0.001-0.05) 
reduced by HSA (40 mg/mL) after a 15-120 min incubation 
(Fig. 3C). Moreover, 14C-PIH uptake was slightly (p<0.05) 
reduced by HSA (5 mg/mL), BSA (40 mg/mL) and Tf (40 
mg/mL) after 120 min relative to the control. Conversely, 
no overall significant (p>0.05) difference was evident 
for 14C-PIH uptake in Tf- containing media (5 mg/mL) 
compared to the control (Fig. 3C).
Collectively, the cellular uptake of 14C-Dp44mT 
was markedly increased by HSA (40 mg/mL), in contrast 
to Tf or BSA at the same concentration. This observation 
indicated that HSA, rather than other plasma proteins or 
albumin from another species, specifically mediated an 
increase in 14C-Dp44mT uptake. Conversely, 14C-Bp4eT 
and 14C-PIH uptake was reduced by HSA (40 mg/mL). 
These findings correlate with the appreciable binding 
affinity of 14C-Bp4eT and 14C-PIH for HSA (Fig. 2A), 
resulting in a decrease in 14C-Bp4eT and 14C-PIH uptake 
by SK-N-MC cells. Overall, these results indicate HSA 
has pronounced differential effects on 14C-ligand uptake 
despite their structural similarities (Fig. 1A).
Membrane and Internalized Uptake of 
14c-Dp44mt by cells are Increased by HsA, while 
14c-bp4et and 14c-PIH Uptake are Decreased
To determine if HSA altered the cellular distribution 
of the 14C-chelators, uptake into the internalized and 
membrane (non-internalized) fractions were assessed 
after incubation with the general protease, Pronase, using 
standard procedures [49-52] (Fig. 3D). HSA significantly 
(p<0.001) increased internalized and membrane uptake 
of 14C-Dp44mT by cells relative to the control (Fig. 3D). 
In contrast, HSA significantly (p<0.001) decreased the 
internalized and membrane uptake of 14C-Bp4eT compared 
to the control (Fig. 3D). Similarly, incubation of cells with 
HSA significantly (p<0.05) decreased internalized 14C-PIH 
uptake, while membrane uptake of 14C-PIH was only 
slightly reduced (p>0.05). Collectively, HSA increased 
the internalized and membrane uptake of 14C-Dp44mT, 
while decreasing the internalized and membrane uptake 
of 14C-Bp4eT and to a slightly lesser extent 14C-PIH (Fig. 
3D).
HsA Markedly Increases 14c-Dp44mt Uptake 
as a Function of temperature and Ligand 
concentration
To elucidate the mechanism involved in HSA-
potentiated 14C-Dp44mT uptake, the temperature 
dependence of this process over a concentration range 
(0.1-150 µM) was examined during a 2 h incubation at 4oC 
or 37oC in the presence or absence of HSA (40 mg/mL) 
using SK-N-MC cells (Fig. 3E). In the absence of HSA, 
14C-Dp44mT uptake at 37oC saturated at approximately 
5-10 µM (see inset Fig. 3E), as reported previously, 
suggesting the presence of a putative Dp44mT receptor/
carrier [34]. The addition of HSA significantly (p<0.001-
0.01) increased 14C-Dp44mT uptake at 37oC at ligand 
concentrations greater than ≥25 µM (Fig. 3E). Saturation 
of the HSA-stimulated uptake mechanism occurred at a 
Dp44mT concentration of 100 µM (Fig. 3E). These two 
saturation events suggest two different Dp44mT-binding 
sites in the presence or absence of HSA.
Examining 14C-Dp44mT uptake in the presence of 
HSA using non-linear regression analysis demonstrated a 
high correlation (r2 = 0.97) and resulted in a Bmax value of 
2.92 ± 0.12 x 107 molecules/cell (n = 9) and a Kd value 
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Figure 3: (A-C): Effect of human serum albumin (HSA), bovine serum albumin (BSA) and transferrin (Tf) on the uptake of: 
(A) 14C-Dp44mT; (B) 14C-Bp4eT; and (C) 14C-PIH by the human SK-N-MC neuroepithelioma cell line at 37oC. The cells were 
incubated in media containing the 14C-chelator (25 µM) in the presence and absence of HSA (5 or 40 mg/mL), BSA (40 mg/mL) or Tf (5 or 
40 mg/mL) for 0-120 min at 37oC. The cells were then placed on ice, washed 4 times using ice-cold PBS, removed from the plates and the 
radioactivity was quantified. (D) HSA potentiates 14C-Dp44mT uptake in both the membrane and internalized compartments. SK-N-MC 
cells were incubated with 14C-Dp44mT, 14C-Bp4eT or 14C-PIH (25 μM) with or without HSA (40 mg/mL) for 2 h/37oC, washed in cold PBS, 
treated with Pronase (1 mg/mL) for 30 min/4oC and centrifuged at 10,000 rpm/1 min. The medium was collected to represent the Pronase-
sensitive membrane-bound fraction and the cells were resuspended in PBS to represent the Pronase-insensitive internalized component. 
Radioactivity was quantified and results were expressed as described above. *, p<0.05; ***, p<0.001 relative to the corresponding control. 
(E) Stimulation of HSA uptake of 14C-Dp44mT is saturable. Uptake of 14C-Dp44mT uptake as a function of concentration in the presence 
or absence of HSA (40 mg/mL) by SK-N-MC cells at 37oC. SK-N-MC cells were incubated with either HSA (40 mg/mL)-containing media 
or protein-free media with 14C-Dp44mT (0.1-150 μM) for 2 h at 4oC or 37oC. The cells were then placed on ice, washed 4 times using 
ice-cold PBS, removed from the plates and the radioactivity quantified. Inset shows the uptake of 14C-Dp44mT (0.1-50 μM) by SK-N-MC 
cells after a 2 h/37oC incubation. (F) 14C-Dp44mT uptake is competitively inhibited by excess HSA. 14C-Dp44mT uptake in the presence 
of increasing concentrations of HSA or BSA at 37oC. SK-N-MC cells were incubated in media containing 14C-Dp44mT (25 μM) in the 
presence or absence of HSA or BSA (20-250 mg/mL) for 2 h/37oC. The remainder of the experiment was performed as described above 
in Fig. 3F. **, p<0.01; ***, p<0.001 relative to the control. (G) Efflux of 14C-Dp44mT from SK-N-MC cells. Cells were prelabeled with 
14C-Dp44mT (25 µM) for 2 h/37oC in the presence or absence of HSA (40 mg/mL), washed 4 times on ice and then reincubated for 0-60 
min in medium containing HSA (40 mg/mL) and the release of 14C-Dp44mT assessed. Results are expressed as a percentage of 14C-Dp44mT 
released (mean ± S.E.M.) of at least 3 experiments.
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of 65 ± 6 µM (n = 9). In the absence of HSA, non-linear 
regression also indicated a high correlation (r2 = 0.96), 
but resulted in a lower Bmax value of 1.20 ± 0.04 x 10
7 
molecules/cell (n = 9) and a lesser Kd value of 33 ± 3 µM 
(n = 9). Of relevance, in a previous study using SK-N-
MC cells under different experimental conditions, a higher 
Bmax value (4.28 x 10
7 molecules of chelator/cell) and a 
lower Kd value (2.45 µM) were observed for Dp44mT 
uptake in the absence of HSA [34]. These dissimilar 
results are probably due to the presence of 10% (v/v) FCS 
in the earlier study [34], which is known to affect cellular 
metabolism, receptor dynamics and expression [49, 50, 
53].
As demonstrated previously in the absence of HSA 
[34], 14C-Dp44mT uptake as a function of concentration 
was temperature-dependent, with a significant (p<0.001) 
decrease in cellular 14C-Dp44mT uptake being observed 
at 4oC relative to 37oC at all concentrations (Fig. 3E). 
At 37oC, the cell is metabolically active and results in 
receptor recycling [51, 54, 55]. Thus, the 14C-ligand 
can label receptors at both the plasma membrane and 
those cycling intracellularly [51, 54, 55]. In contrast, at 
4oC, cells are metabolically inactive, inhibiting receptor 
cycling. Thus, only plasma membrane-bound receptors are 
labeled with the ligand, leading to a decrease in uptake 
relative to that found at 37oC [51, 54, 55].
Notably, 14C-Dp44mT uptake as a function 
of concentration in the presence of HSA was also 
temperature-dependent. In fact, a significant (p<0.001-
0.01) decrease in 14C-Dp44mT uptake in the presence of 
HSA was observed at 4oC relative to 37oC at all Dp44mT 
concentrations (Fig. 3E). The saturable and temperature-
dependent nature of 14C-Dp44mT uptake in the presence 
of HSA suggested a mechanism consistent with a carrier/
receptor-mediated uptake process.
Excess Non-Physiological Levels of Unlabeled 
HsA Decrease Dp44mt Uptake by cells
Next, the effect of increasing HSA and BSA 
concentrations (20-250 mg/mL) on 14C-Dp44mT uptake 
by SK-N-MC cells was examined after 2 h/37oC (Fig. 
3F). These studies were performed to determine the 
ability of excess HSA levels to compete with and inhibit 
the enhanced HSA-mediated uptake of 14C-Dp44mT. 
Furthermore, considering BSA (40 mg/mL) did not 
increase 14C-Dp44mT uptake (Fig. 3A), relevant control 
studies were also performed using the same concentrations 
of BSA (20-250 mg/mL; Fig. 3F).
As evident in Fig. 3A, BSA did not significantly 
(p>0.05) increase 14C-Dp44mT uptake at all concentrations 
tested (Fig. 3F). In fact, BSA (100 mg/mL) significantly 
(p<0.01) decreased 14C-Dp44mT uptake to 77 ± 4% of the 
control (i.e., 14C-Dp44mT in the absence of protein; Fig. 
3F). In contrast, as observed in Fig. 3A and E, 14C-Dp44mT 
uptake was significantly (p<0.001-0.01) increased in the 
presence of HSA (20-100 mg/mL) relative to the control 
(i.e., 14C-Dp44mT in the absence of protein; Fig. 3F). 
However, after the pronounced increase in 14C-Dp44mT 
uptake up to the physiological HSA concentration in 
plasma (40 mg/mL), 14C-Dp44mT uptake then decreased 
as the HSA concentration increased up to 100 and 250 mg/
mL (Fig. 3F). In fact, at this latter HSA concentration, a 
marked and significant (p<0.01) decrease in 14C-Dp44mT 
uptake was observed in comparison to physiological HSA 
levels (40 mg/mL; Fig. 3F). Thus, it can be speculated 
that the decrease in 14C-Dp44mT uptake at higher HSA 
concentrations relative to physiological levels may be due 
to the ability of excess HSA to compete with 14C-Dp44mT-
bound HSA for the cellular HSA-binding site.
Effect of HsA on 14C-Dp44mT Efflux from Cells
We also investigated the effect of HSA on efflux of 
14C-Dp44mT (Fig. 3G), as the stimulatory effects of HSA 
on intracellular uptake of 14C-Dp44mT (Fig. 3D) could 
also be due to its effect on the release of the ligand from 
the cell. For example, decreased efflux of 14C-Dp44mT 
from cells in the presence of HSA could lead to cellular 
accumulation of the ligand. To assess this hypothesis, SK-
N-MC cells were pre-labeled with 14C-Dp44mT (25 µM) 
in the presence or absence of HSA (40 mg/mL) for 2 h at 
37oC. To replicate physiological conditions, the cellular 
efflux of 14C-Dp44mT was then assessed in the presence of 
HSA (40 mg/mL) as a function of time (0-60 min) at 37oC. 
The cellular release of 14C-Dp44mT increased with 
time and reached a plateau at 30 min, where 74.8 ± 2.3% 
of 14C-Dp44mT was released (Fig. 3G). Importantly, the 
pre-labeling of cells with 14C-Dp44mT in the presence 
of HSA did not significantly (p>0.05) alter the efflux of 
14C-Dp44mT at all time points (Fig. 3G). Performing the 
efflux incubation in the absence of HSA also demonstrated 
no difference in 14C-Dp44mT release when cells were 
labeled in the presence or absence of HSA (data not 
shown). In summary, these data indicate that other factors, 
besides the efflux of the ligand, were responsible for the 
enhanced cellular uptake of 14C-Dp44mT in the presence 
of HSA.
the Increase in 14c-Dp44mt Uptake Mediated by 
HsA is Observed in a Variety of Neoplastic and 
Normal cell-types
To understand if the increase of 14C-Dp44mT uptake 
or inhibition of 14C-Bp4eT and 14C-PIH uptake mediated 
by HSA were specific to certain cell-types, 14C-chelator 
uptake in the presence and absence of HSA was examined 
using a range of cells (Supplementary Fig. 2A-C). The 
uptake of the 14C-chelators was examined in a variety of 
immortal cancer/transformed cell-types (i.e., SK-N-MC 
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neuroepithelioma, SK-Mel-28 melanoma, MCF-7 breast 
cancer, DMS-53 lung carcinoma, HepG2 hepatoma, 
HK-2 immortalized kidney proximal tubule epithelial 
cells) and normal, mortal cells (i.e., HUVECs and MRC-5 
fibroblasts) in HSA-containing (40 mg/mL) or protein-free 
media for 2 h/37oC (Supplementary Fig. 2A-C).
As evident in Fig. 3A, in SK-N-MC cells, 
14C-Dp44mT uptake was significantly (p<0.01) increased 
by HSA to 300 ± 10% of the control (i.e., ligand without 
HSA; Supplementary Fig. 2A). Additionally, HSA also 
significantly (p<0.01-0.001) increased 14C-Dp44mT 
uptake in SK-Mel-28, MCF-7, HUVEC and DMS-53 
cells to 169-372% of the control, demonstrating that this 
effect was not specific to SK-N-MC cells (Supplementary 
Fig. 2A). Interestingly, HSA did not significantly (p>0.05) 
increase uptake of 14C-Dp44mT in MRC-5, HepG2 and 
HK-2 cells compared to the control (Supplementary Fig. 
2A). In fact, HSA slightly, but significantly (p<0.01), 
decreased 14C-Dp44mT uptake by HK-2 cells versus the 
control (Supplementary Fig. 2A).
In contrast to 14C-Dp44mT, 14C-Bp4eT uptake was 
significantly (p<0.01-0.001) decreased in the presence of 
HSA (40 mg/mL) in all cell-types studied (Supplementary 
Fig. 2B). Similarly to 14C-Bp4eT, 14C-PIH uptake was also 
significantly (p<0.01-0.05) inhibited in the presence of 
HSA (40 mg/mL) in all cell-types examined, except for 
DMS-53, MRC-5 and HK-2 cells, where a non-significant 
(p>0.05) decrease was observed (Supplementary Fig. 2C). 
Hence, in contrast to 14C-Dp44mT, these results indicated 
that the ability of HSA to inhibit 14C-Bp4eT or 14C-PIH 
uptake was independent of the cell-type assessed.
Collectively, these studies demonstrated that 
the HSA-mediated increase in 14C-Dp44mT uptake 
and decrease in 14C-Bp4eT and 14C-PIH uptake was 
observed in a variety of normal and neoplastic cell-types. 
Considering this, albumin receptors/binding sites have 
been previously reported in a variety of cell-types [36]. 
Hence, we examined the expression of five known albumin 
receptors/binding proteins, namely: calreticulin [56], 
hnRNP [56], cubilin [57], SPARC [58] and FcRn [59] in 
the immortal and normal/mortal cell lines assessed above. 
However, no direct correlation was observed between 
the expression of these proteins (data not shown) and 
HSA-mediated 14C-Dp44mT uptake by these cell-types 
(Supplementary Fig. 2A). This observation suggested that 
HSA-mediated Dp44mT uptake was independent of these 
albumin-binding proteins.
HSA Specifically Binds to Cells, but Dp44mT, 
bp4et or PIH, do not Affect 125I-Labeled HsA 
Uptake
To further elucidate the mechanisms behind the 
potentiation of 14C-Dp44mT targeting by HSA, the 
cellular uptake of 125I-labeled HSA by SK-N-MC cells 
was examined in the presence and absence of unlabeled 
Dp44mT, Bp4eT or PIH (25 µM; Fig. 4A-B). It was 
hypothesized that cellular stress induced by Dp44mT may 
increase 125I-HSA-mediated uptake, and thus, potentiate 
the transport of the chelator into the cell. In these studies, 
the uptake of 125I-HSA (0.001-10 mg/mL) was performed 
as a function of concentration after a 2 h/37oC incubation 
with SK-N-MC cells in the presence and absence of 
Dp44mT (Fig. 4A). 
The total uptake of 125I-HSA by SK-N-MC cells 
plateaued at approximately 5-7.5 mg/mL and occurred 
by a single exponential process, suggesting a saturable 
binding site (Bmax: 1.46 ± 0.10 x 10
7 molecules/cell; Kd: 
62 ± 11 µM; Fig. 4A). Of note, previous studies have 
identified Kd values for albumin-binding sites in the 
micomolar range (0.25 - 15.1 µM) in other cell-types [60, 
61]. The internalized (Pronase-insensitive) and membrane 
(Pronase-sensitive) uptake of 125I-HSA also increased 
as a function of 125I-HSA concentration and again 
plateaued at approximately 5-7.5 mg/mL (Fig. 4A). These 
observations suggested a saturable membrane-binding site 
which became internalized, potentially by a process of 
receptor-mediated endocytosis, which has been described 
previously for HSA receptors [36, 62, 63]. Notably, only 
a fraction of 125I-HSA (7.5 mg/mL) was internalized, with 
approximately 90% remaining membrane-bound (Fig. 
4A). Additionally, the internalized or membrane-bound 
125I-HSA uptake was not significantly (p>0.05) altered in 
the presence of Dp44mT (Fig. 4A).
To further elucidate the differential effects of HSA 
on ligand uptake, 125I-HSA (7.5 mg/mL) uptake was 
examined in the presence of unlabeled Dp44mT, Bp4eT 
and PIH (25 µM) as a function of time (5-30 min; Fig. 
4Bi-iii). This concentration of HSA was utilized as uptake 
became clearly saturated at this concentration (Fig. 4A). 
In parallel with these studies, the uptake of 14C-Dp44mT, 
14C-Bp4eT and 14C-PIH (25 µM) was performed as a 
function of time (5-30 min) in the presence or absence 
of HSA (7.5 mg/mL) to assess the effect of this protein 
on 14C-chelator uptake (Fig. 4Ci-iii). Irrespective of the 
presence or absence of the ligands, HSA uptake was 
biphasic, consisting of a rapid increase in internalized 
(Pronase-insensitive) and membrane-bound (Pronase-
sensitive) 125I-HSA uptake followed by a plateau after 
5 min of incubation (Fig. 4Bi-iii). These kinetics are 
consistent with the initial binding of 125I-HSA to its 
receptor, uptake by endocytosis, followed by release of 
the ligand by exocytosis, as described for other plasma 
proteins in other neoplastic cell-types [50]. As found for 
125I-HSA uptake as function of concentration (Fig. 4A), 
membrane-bound 125I-HSA was markedly greater than the 
internalized 125I-HSA uptake, with approximately 10% of 
the total 125I-HSA being internalized (8.5 x 106 molecules 
of HSA/cell; Fig. 4Bi-iii). The internalized or membrane-
bound 125I-HSA uptake was not significantly (p>0.05) 
altered in the presence of Dp44mT, Bp4eT, or PIH (Fig. 
Oncotarget10384www.impactjournals.com/oncotarget
Figure 4: (A) Dp44mT has no effect on the uptake of 125I-HSA by human SK-N-MC cells as a function of concentration 
at 37oC. SK-N-MC cells were incubated in media with 125I-HSA (0.001-10 mg/mL) in the presence and absence of unlabeled Dp44mT 
(25 μM) for 2 h/37oC. Cells were washed in cold PBS, treated with Pronase (1 mg/mL) for 30 min/4oC and radioactivity of the resulting 
Pronase-sensitive (membrane-bound) fraction and the Pronase-insensitive (cellular fraction) was assessed. Results are expressed as mean 
± S.E.M. from 3 experiments. (B) Effect of unlabeled (i) Dp44mT, (ii) Bp4eT, or (iii) PIH on the uptake of 125I-HSA by SK-N-MC cells as 
a function of time at 37oC. SK-N-MC cells were incubated with 125I-HSA (7.5 mg/mL) with or without unlabeled Dp44mT, Bp4eT, or PIH 
(25 μM) for 30 min/37oC. Subsequent steps were performed as above. (C) Effect of HSA (7.5 mg/mL) on (i) 14C-Dp44mT, (ii) 14C-Bp4eT 
or (iii) 14C-PIH (25 μM) uptake by SK-N-MC cells as a function of time at 37oC. Experiments were performed in parallel to those in Figure 
6B, with the methodology being the same as that described in Figure 4A-C.
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4Bi-iii).
As shown previously (Fig. 3A), 14C-Dp44mT 
uptake was significantly (p<0.001) increased in the 
presence of unlabeled HSA (7.5 mg/mL) at all time points 
examined (Fig. 4Ci). Moreover, as evident in Fig. 3B 
and C, unlabeled HSA significantly (p<0.05) decreased 
14C-Bp4eT and 14C-PIH uptake relative to the control (Fig. 
4Cii-iii). Collectively, these studies demonstrated the 
altered uptake of the 14C-chelators in the presence of HSA 
was not due to altered HSA uptake.
Effect of Glucose-Deprivation, Metabolic and 
Endocytosis Inhibitors, temperature and 
Lysosomotropic Agents on Dp44mt Uptake in the 
Presence and Absence of HsA 
To differentiate between the cellular mechanisms 
involved in 14C-Dp44mT uptake in the presence and 
absence of HSA, a series of conditions were utilized 
examining: (1) glucose-deprivation and several well 
characterized metabolic inhibitors [34, 35]; (2) incubation 
temperature; (3) an endocytosis inhibitor [64-67]; (4) and 
lysosomotropic agents [52, 65, 68]. The effects of these 
agents on 14C-Dp44mT uptake were compared to parallel 
experiments examining uptake of 125I-HSA or the positive 
control, 59Fe-125I-Tf. This comparison was performed as 
Figure 5: The effect of metabolic and endocytosis inhibitors, temperature, lysosomotropic agents or a 100-fold excess 
of protein on the uptake of 14c-Dp44mt in the presence and absence of HsA, or 59Fe-125I-tf or 125I-HsA uptake. SK-N-
MC cells were pre-incubated with: (1) FCS-free media; (2) FCS- and glucose-free media (-Glu); (3) FCS- and Glu-free media containing the 
known metabolic inhibitors sodium azide (30 mM) or sodium cyanide (5 mM); (4) FCS-free media at 4˚C; (5) FCS-free media containing 
the endocytosis inhibitor, phenylglyoxal (PGO; 5 mM); (6) FCS-free media containing the lysosomotropic agents, ammonium chloride 
(15 mM) or methylamine (15 mM); or (7) 100-fold excess unlabeled Fe-Tf or HSA (75 µM) for 30 min at 37˚C unless otherwise stated. 
Following this, the uptake of (A) 14C-Dp44mT (25 µM) in the presence or absence of HSA (40 mg/mL), (B-C) 59Fe-125I-Tf (0.75 µM) or 
(D) 125I-HSA (0.75 µM) by cells was assessed under the continuation of these 7 incubation conditions for 1 h. The cells were then washed 
and processed for quantification. Results are expressed as mean ± S.E.M. (3 experiments). *, p<0.05; **, p<0.01; ***, p<0.001 relative to 
the corresponding control.
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59Fe-125I-Tf is well known to be internalized by receptor-
mediated endocytosis in SK-N-MC cells and many other 
cell-types [52, 69-71]. In terms of 59Fe-125I-Tf uptake, we 
have assessed both 59Fe bound to the specific binding sites 
of the protein (59Fe-Tf), as well as the protein itself (125I-
Tf; [52, 69-71]).
(1) Effect of Glucose-Deprivation and Metabolic 
Inhibitors on 14c-Dp44mt Uptake
We previously demonstrated that 14C-Dp44mT 
uptake by SK-N-MC cells was dependent on ATP 
synthesis via oxidative phosphorylation in the absence of 
HSA, as they could be partly inhibited using the metabolic 
inhibitors, sodium azide (30 mM), or sodium cyanide (5 
mM) [34], which inhibit complex IV of the mitochondrial 
electron transport chain [72]. In this investigation, the 
same protocol was used as described in [34], in which 
cells were preincubated with inhibitors for 30 min/37oC, 
followed by the addition of 14C-Dp44mT or 14C-Dp44mT 
and HSA to these solutions, which were then incubated 
with the cells for 1 h/37oC. We previously demonstrated 
that these same incubation conditions with inhibitors 
markedly suppressed cellular ATP levels [34] that are vital 
for many cellular processes e.g., endocytosis [52, 70, 73].
Incubation of cells in the absence of glucose 
(-Glu) led to a slight, but significant (p<0.05) decrease 
in 14C-Dp44mT uptake relative to cells incubated with 
glucose-containing medium (i.e., control; Fig. 5A). 
Similarly to previous studies examining 14C-Dp44mT 
uptake in the absence of HSA [34], herein we also show 
that in glucose-free medium containing sodium azide or 
sodium cyanide, 14C-Dp44mT uptake was significantly 
(p<0.001) reduced to 65 ± 4% and 78 ± 6%, respectively, 
relative to glucose-containing control medium (Fig. 
5A). In contrast, no significant (p>0.05) difference in 
14C-Dp44mT uptake in the presence of HSA versus the 
control was shown using glucose-free medium (-Glu) 
or these inhibitors (Fig. 5A). These data suggest HSA-
mediated 14C-Dp44mT uptake was less reliant on 
metabolic energy relative to 14C-Dp44mT uptake alone.
(2) Effect Incubation temperature on 14c-Dp44mt 
Uptake
Additional studies demonstrated that 14C-Dp44mT 
uptake in the absence of HSA was significantly (p<0.001) 
reduced at 4oC relative to 37oC (Fig. 5A). A similar and 
significant (p<0.001) inhibitory effect of incubation at 4oC 
was also observed on HSA-mediated 14C-Dp44mT uptake 
relative to uptake observed at 37oC (Fig. 5A). Hence, 
14C-Dp44mT uptake in the presence and absence of HSA 
was dependent on incubation temperature.
(3 & 4) Effect of an Endocytosis Inhibitor and 
Lysosomotropic Agents on 14c-Dp44mt Uptake
Experiments then assessed the role of endocytosis 
and endosomal/lysosomal acidification on 14C-Dp44mT 
uptake in the presence and absence of HSA. In these 
studies, the well-characterized endo-/exocytosis inhibitor, 
phenylglyoxal (PGO; 5 mM; [64-66]), or the well known 
lysosomotropic agents, ammonium chloride (15 mM) or 
methylamine (15 mM), were assessed [52, 65, 68]. After 
incubation with PGO, there was a significant (p<0.001) 
increase in 14C-Dp44mT uptake relative to the control in 
the presence or absence of HSA (Fig. 5A). Considering 
that PGO inhibits both endocytosis and exocytosis [64-66], 
it can be speculated that the PGO-enhanced accumulation 
of 14C-Dp44mT was due to the inhibition of exocytosis, 
thereby preventing efflux of this ligand.
In contrast, both lysosomotropic agents had no 
significant (p>0.05) effect on 14C-Dp44mT uptake in the 
presence or absence of HSA relative to the control (Fig. 
5A). Considering the failure of PGO and lysosomotropic 
agents to inhibit 14C-Dp44mT uptake with or without 
HSA, and the fact that they significantly (p<0.001-0.01) 
inhibit 59Fe- and 125I-Tf uptake from 59Fe-125I-Tf (see Fig. 
5B, C), these data suggest that 14C-Dp44mT uptake was 
independent of endocytosis and the acidification of the 
endosomal/lysosomal compartment.
Effect of Glucose-Deprivation, Metabolic and 
Endocytosis Inhibitors, temperature and 
Lysosomotropic Agents on 59Fe-125I-transferrin 
and 125I-HsA Uptake
In parallel studies implementing the same incubation 
conditions as the 14C-Dp44mT uptake experiments (Fig. 
5A), the cellular uptake of 59Fe-125I-Tf (0.75 µM; Fig. 5B-
C) or 125I-HSA (0.75 µM; Fig. 5D) were investigated, as 
uptake of these proteins are well characterized [52, 65, 70, 
73]. The uptake of 59Fe-125I-Tf and 125I-HSA by cells was 
significantly (p<0.001-0.01) inhibited in the absence of 
glucose relative to media containing glucose (control; Fig. 
5B-D). This effect of glucose-free medium was generally 
potentiated in the presence of sodium azide and sodium 
cyanide, decreasing 59Fe-Tf, 125I-Tf and 125I-HSA uptake 
to 4-14%, 23-24% and 67-79% of the control, respectively 
(Fig. 5B-D). Hence, similarly to 14C-Dp44mT uptake 
(Fig. 5A), 59Fe-125I-Tf and 125I-HSA uptake was dependent 
on mitochondrial electron transport chain activity 
(Fig. 5B-D). In contrast, this was markedly different to 
14C-Dp44mT uptake in the presence of HSA (Fig. 5A), 
that was independent of the inhibition of mitochondrial 
electron transport chain. 
Cells incubated at 4oC internalized significantly 
(p<0.001) less 59Fe-Tf, 125I-Tf, or 125I-HSA than those 
incubated at 37oC (Fig. 5B-D). Incubation of cells with the 
endo-/exocytosis inhibitor, PGO, or the lysosomotropic 
agents, ammonium chloride or methylamine, markedly 
and significantly (p<0.001-0.01) inhibited 125I-Tf (Fig. 
5B) and 59Fe-Tf uptake (Fig. 5C). Similarly, the uptake 
of 125I-HSA was significantly (p<0.001) inhibited in the 
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presence of PGO (Fig. 5D). This observation suggests 
that 14C-Dp44mT enters cells independently of 125I-HSA, 
as 14C-Dp44mT uptake in the presence or absence 
of HSA was significantly (p<0.001) increased upon 
incubation with PGO (Fig. 1A). In contrast to 59Fe-Tf 
or 125I-Tf uptake, 125I-HSA uptake was not significantly 
(p>0.05) altered in the presence of the lysosomotropic 
agents, ammonium chloride or methylamine (Fig. 5D). 
Importantly, 59Fe-Tf, 125I-Tf, or 125I-HSA uptake was 
significantly (p<0.001) inhibited upon the addition of a 
100-fold excess of the unlabeled protein, namely Fe-Tf 
or HSA, respectively (Fig. 5B-D), suggesting competition 
between the unlabeled and labeled protein for the same 
binding sites. These results agree with previous studies 
demonstrating 59Fe-Tf, 125I-Tf and 125I-HSA uptake occur 
via energy- and temperature-sensitive endocytosis [69, 70, 
74, 75].
Together, these data indicate in contrast to 59Fe-Tf, 
125I-Tf and 125I-HSA uptake by cells, 14C-Dp44mT uptake 
in the presence of HSA was insensitive to glucose levels, 
inhibition of energy metabolism and the suppressive 
effects of lysosomotropic agents or an endo-/exocytosis 
inhibitor. These observations suggested the HSA-
stimulated mechanism of 14C-Dp44mT uptake occurred 
by a different pathway to the uptake of either 125I-HSA 
or 59Fe-125I-Tf that occur by endocytosis or endocytosis 
requiring endosomal acidification, respectively [52, 69-
71, 74, 75].
HsA Enhances the Anti-Proliferative Activity of 
Dp44mt and Inhibits that of bp4et and PIH
Considering the increased uptake of 14C-Dp44mT in 
the presence of HSA (Fig. 3A, D, E), the effect of HSA on 
the anti-proliferative activity of Dp44mT was examined in 
SK-N-MC cells (Fig. 6A). Additionally, the effect of HSA 
on the anti-proliferative activity of Bp4eT and PIH were 
also assessed (Fig. 6A), considering the inhibitory effects 
of HSA on 14C-Bp4eT and 14C-PIH uptake (Fig. 3B-C). 
In these experiments, cells were incubated with Dp44mT 
(30-120 µM), Bp4eT (30-120 µM), PIH (150-600 µM) or 
the vehicle alone (control) in the presence or absence of 
HSA (40 mg/mL) for 24 h/37oC (Fig. 6A).
HSA significantly (p<0.001) increased the anti-
proliferative activity of Dp44mT relative to Dp44mT 
alone, leading to a decrease in its IC50 (Fig. 6A). In 
fact, after a 24 h incubation, HSA decreased the IC50 of 
Dp44mT by ≈ 1.6-fold to 40 ± 2 µM in comparison to 
Dp44mT alone (66 ± 4 µM; Fig. 6A). As an additional 
control, the anti-proliferative activity of Dp44mT was 
also examined in the presence of BSA (40 mg/mL; data 
not shown). However, the IC50 of Dp44mT was not 
significantly (p>0.05) altered in the presence of BSA (IC50: 
72 ± 2 μM) relative to the ligand alone. This observation 
is in agreement with our studies showing that BSA did not 
significantly (p>0.05) alter cellular 14C-Dp44mT uptake 
(Fig. 3A).
In contrast to Dp44mT, the anti-proliferative activity 
of Bp4eT was significantly (p<0.001) reduced by HSA, 
leading to an increase in the IC50 (81 ± 4 µM) relative to its 
activity in the absence of HSA (IC50: 38 ± 3 µM; Fig. 6A). 
Similarly, HSA significantly (p<0.001) increased the IC50 
of PIH to 507 ± 7 µM compared to the ligand alone (IC50: 
426 ± 14 µM; Fig. 6A). These data are in good agreement 
with our 14C-chelator uptake experiments and indicate that 
the HSA-mediated increase in 14C-Dp44mT uptake (Fig. 
3A) results in its enhanced anti-proliferative efficacy (Fig. 
6A). In contrast, the ability of HSA to decrease cellular 
14C-Bp4eT and 14C-PIH uptake (Fig. 3B-C) decreased anti-
proliferative activity of both ligands (Fig. 6A).
HsA Enhances the Apoptotic Activity of Dp44mt 
and Inhibits that of bp4et
In contrast to PIH and Bp4eT, the cellular uptake 
and cytotoxicity of Dp44mT was enhanced in the presence 
of HSA (Figs. 3A, D, 6A). Thus, it was important to 
examine the effects of HSA on the ability of these ligands 
to induce apoptosis. In order to do this, the effects of 
Dp44mT, Bp4eT and PIH (50 µM) on the levels of the 
apoptotic marker, cleaved poly ADP-ribose polymerase 
(PARP; [76, 77]), were examined in SK-N-MC cells after 
a 6 or 12 h incubation at 37oC in the presence or absence 
of HSA (40 mg/mL; Fig. 6B).
After a 6 h incubation, Dp44mT resulted in a 19.4-
fold increase in cleaved PARP levels relative to the control 
(Fig. 6Bi). This observation was in good agreement 
with the known ability of Dp44mT to induce apoptosis 
in vitro and in vivo [25, 78, 79]. The level of cleaved 
PARP upon co-incubation of Dp44mT and HSA for 6 h 
was significantly (p<0.001) increased relative to both the 
control and Dp44mT treatment alone (Fig. 6Bi). In fact, 
cleaved PARP levels were 1.3-fold greater in Dp44mT 
+ HSA treated cells relative to Dp44mT alone. These 
results suggest HSA enhanced the ability of Dp44mT to 
induce apoptosis at this early time point. In contrast, a 6 h 
incubation with Bp4eT or PIH in the presence or absence 
of HSA did not result in significantly (p>0.05) increased 
cleaved PARP relative to their controls (Fig. 6Bi).
At the 12 h time point, Dp44mT alone and Dp44mT 
+ HSA significantly (p<0.001) increased cleaved PARP 
relative to their controls (i.e., control medium and control 
medium + HSA, respectively; Fig. 6Bii). Cleaved PARP 
levels in cells co-treated with Dp44mT + HSA showed 
a significant (p<0.01) 1.2-fold increase relative to cells 
treated with Dp44mT alone. Cells treated with Bp4eT 
alone demonstrated significantly (p<0.001) increased 
cleaved PARP relative to the control (Fig. 6Bii). However, 
this effect was abolished upon incubating cells with 
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Figure 6: the effect of HsA on the anti-proliferative and apoptotic activity of Dp44mt, bp4et and PIH. (A) The anti-
proliferative activity of Dp44mT, Bp4eT and PIH in the presence of HSA for 24 h/37oC. Cells were incubated with Dp44mT (30-120 µM), 
Bp4eT (30-120 µM), PIH (150-600 µM) or vehicle alone (control) in the presence or absence of HSA (40 mg/mL) for 24 h/37oC. Trypan 
blue was used to obtain direct cell counts and to determine IC50 values. Results are expressed as mean ± S.E.M. (3 experiments). ***, 
p<0.001 relative to the corresponding control. (B) Levels of cleaved PARP following treatment of SK-N-MC cells with Bp4eT, Dp44mT 
or PIH (50 µM) in the presence and absence of HSA (40 mg/mL) after (i) 6 h or (ii) 12 h/37oC. Western blots are typical of 3 independent 
experiments. Results are expressed as mean ± S.E.M. (3 experiments). **, p<0.01; ***, p<0.001.
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Bp4eT in the presence of HSA, resulting in cleaved PARP 
levels that were significantly (p<0.001) decreased relative 
to Bp4eT alone and was comparable to the control (Fig. 
6Bii). Thus, HSA inhibited the ability of Bp4eT to induce 
cleaved PARP. In contrast, cells incubated for 12 h with 
PIH in the presence or absence of HSA did not result in 
cleaved PARP and were comparable to their controls (Fig. 
6Bii).
Collectively, these results demonstrated that 
HSA was able to significantly (p<0.001-0.01) enhance 
the apoptotic effects of Dp44mT at 6 and 12 h and this 
reflected its increased cellular uptake (Fig. 3A, D, E) and 
anti-proliferative activity (Fig. 6A) of Dp44mT upon 
HSA co-treatment. In contrast, the presence of HSA was 
able to inhibit the apoptotic activity of Bp4eT after 12 
h, which probably results from the decreased 14C-Bp4eT 
uptake observed upon incubation with HSA (Fig. 3B, D). 
On the other hand, PIH did not induce marked levels of 
PARP cleavage and this reflects the poor anti-proliferative 
activity of this agent [37] relative to Dp44mT [24, 25] and 
Bp4eT [38] (Fig. 6A).
DIscUssION
Dp44mt, bp4et and PIH bind to HsA
In this investigation, studies were performed to 
determine whether Dp44mT, Bp4eT or PIH were able to 
directly bind to albumin using fluorescence spectroscopy 
and equilibrium dialysis studies. These experiments 
demonstrated that all the ligands bind to HSA, although 
with different avidities (Fig. 1-2). In fact, equilibrium 
dialysis experiments indicated that 14C-Bp4eT became 
bound to HSA with similar avidity to 14C-PIH, while 
14C-Dp44mT was most weakly bound to the protein (Fig. 
2A). Molecular docking studies also supported these 
conclusions (Supplementary Fig. 1). Importantly, these 
findings indicating the avid binding of Bp4eT and PIH to 
HSA could explain the decreased uptake of these agents 
by cells in the presence of this protein (Fig. 3B-D). In 
fact, in the absence of HSA, Bp4eT and PIH are known 
to enter cells via passive diffusion [35]. Considering this, 
HSA may act as an extracellular ‘sink’, preventing the 
passive diffusion of Bp4eT and PIH into cells (Fig. 7A). 
Consequently, HSA did not enhance 14C-Bp4eT or 14C-PIH 
uptake or anti-proliferative activity, but conversely, 
decreased it (Fig. 3B-D, 7A).
14C-Dp44mT Uptake is Specifically Enhanced by 
HsA
In contrast to Bp4eT and PIH (Fig. 3B-C), 
Dp44mT uptake is markedly increased in the presence 
of physiological concentrations of HSA in the plasma 
(40 mg/mL) as a function of time (Fig. 3A) and 
concentration (Fig. 3E). In comparison, HSA markedly 
decreased 14C-Bp4eT and 14C-PIH uptake (Fig. 3B-C). 
The enhanced 14C-Dp44mT uptake was specific for HSA 
and this observation was supported by two findings. 
First, this effect did not occur in the presence of the same 
concentration of Tf, suggesting a specific interaction 
between Dp44mT and HSA and not other plasma proteins 
(Fig. 3A). Second, stimulation of Dp44mT uptake did not 
occur with albumin from another species, namely BSA 
(75.6% sequence identity to HSA; [5]), demonstrating 
specificity (Fig. 3A).
Previous studies from our laboratory determined 
that the cellular uptake of 14C-Dp44mT occurred via a 
saturable carrier/receptor-mediated mechanism [34] (Fig. 
7B). Evidence for this mechanism was also obtained in 
the current investigation in the absence of HSA, with 
14C-Dp44mT uptake saturating at 5-10 µM (Fig. 3E inset). 
However, the addition of HSA led to a high-capacity, 
saturable, uptake process with saturation occurring at a 
Dp44mT concentration of 100 µM (Fig. 3E). Hence, in 
the presence of HSA, there was evidence of an important 
second saturable mechanism of Dp44mT uptake. 
Moreover, HSA-stimulated Dp44mT uptake was inhibited 
by an excess of unlabeled HSA (Fig. 3F), suggesting 
excess HSA competes with the Dp44mT-HSA complex 
for HSA membrane-binding sites (Fig. 7C).
14c-Dp44mt Uptake is Increased by HsA in a 
Variety of cell-types 
14C-Dp44mT uptake was also augmented by HSA 
in a variety of cancer cell lines and a non-neoplastic, 
mortal cell-type (Supplementary Fig. 2A). These 
observations demonstrated that the HSA-mediated 
increase of 14C-Dp44mT uptake was a commonly observed 
mechanism that was not unique to one cell-type. However, 
there was some cell-type specificity, and the process was 
not present in some neoplastic and non-neoplastic cells. 
This finding suggested the differential expression of HSA 
receptors/binding sites between cell-types. The HSA-
mediated Dp44mT uptake in a variety of normal and 
neoplastic cells did not correlate with the expression of a 
panel of well known HSA receptors [36], suggesting their 
lack of involvement in the augmented 14C-Dp44mT uptake 
mediated by HSA.
Mechanism of HsA-Mediated Dp44mt Uptake 
Interestingly, 125I-HSA uptake studies indicated 
the presence of saturable HSA-binding sites on SK-N-
MC cells (Fig. 4A), although Dp44mT, Bp4eT or PIH 
did not significantly affect 125I-HSA uptake (Fig. 4Bi-
iii). Indeed, it was demonstrated that in the presence of 
HSA, 14C-Dp44mT uptake occurs through a second, 
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Figure 7: schematic showing the internalization of 14c-bp4et/PIH or 14c-Dp44mt with or without HsA, 125I-HsA or 
59Fe-125I-tf into the cell. (A) 14C-Bp4eT and 14C-PIH are transported by diffusion in the absence of HSA [34]. In the presence of HSA, 
HSA-binding inhibits the uptake of 14C-Bp4eT and 14C-PIH, irrespective of the cell-type. This is due to the high affinity of Bp4eT or PIH 
for HSA, relative to Dp44mT, reducing the levels of free drug available to diffuse into cells. (B) A different mechanism is demonstrated 
by the structurally similar ligand, Dp44mT. 14C-Dp44mT is taken up by cells via a receptor/carrier in the absence of HSA. This uptake 
process is saturable, energy- and temperature-dependent and subject to inhibition by excess unlabeled Dp44mT [34]. (C) In the presence of 
HSA, 14C-Dp44mT uptake occurs through a second, high capacity, saturable process that is cell-type specific and inhibited in the presence 
of excess unlabeled HSA. This process may be facilitated by: (i) a specific HSA-binding site; (ii) the fact most cellular HSA is bound to 
the cell membrane (rather than internalized); and (iii) the relatively low affinity of Dp44mT for HSA. These three properties facilitate 
Dp44mT delivery to cells and create a concentration gradient at the cell surface to enable enhanced uptake via dissociation and passive 
diffusion. The enhanced delivery of 14C-Dp44mT by HSA increases apoptosis and cytotoxicity. (D) 125I-HSA uptake by cells was saturable, 
temperature-dependent, inhibited by excess unlabeled HSA, and sensitive to glucose starvation and inhibitors of energy metabolism or 
endocytosis. Hence, this process was consistent with HSA endocytosis that is known to occur [74, 92]. (E) 59Fe-125I-Tf uptake occurs 
following the binding to its receptor, Tf receptor 1 (TfR1). This process was temperature- and energy-dependent, and subject to inhibition 
by excess unlabeled Tf, an endocytosis inhibitor, and in addition, lysosomotropic agents. Hence, 59Fe-125I-Tf uptake occurs through the well 
characterized process of receptor-mediated endocytosis that requires endosomal acidification [52, 68, 71, 93].
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high capacity, low affinity, saturable process (Fig. 3E) 
that is cell-type specific (Supplementary Fig. 2A) and 
was inhibited in the presence of excess unlabeled HSA 
(Fig. 3F). This uptake process had the following three 
features: (i) it was facilitated by a specific HSA-binding 
site (Fig. 3E, F); (ii) most cellular HSA was bound to the 
cell membrane, rather than internalized (Fig. 4A, Bi-iii); 
and (iii) the avidity of Dp44mT for HSA was relatively 
low (Fig. 2). Together, these three properties suggest 
Dp44mT is delivered to cells in a HSA-dependent manner 
that creates a concentration gradient at the cell surface that 
enhances subsequent uptake via dissociation and passive 
diffusion (Fig. 7C). Indeed, HSA-mediated 14C-Dp44mT 
uptake was not inhibited by glucose-deprivation, metabolic 
inhibitors, an endocytosis inhibitor, or lysosomotropic 
agents (Fig. 5A), indicating a passive uptake process (Fig. 
7C), rather than active endocytosis which occurred for 
125I-HSA (Fig. 5D, 7D) and 59Fe-125I-Tf (Fig. 5B,C, 7E).
In clear contrast to HSA-mediated 14C-Dp44mT 
uptake (Fig. 5A), 125I-HSA uptake by cells was reduced 
by glucose starvation and inhibitors of energy metabolism 
or endocytosis (Figs. 5D, 7D). Together, these data 
suggest augmentation of 14C-Dp44mT uptake in the 
presence of HSA was independent of HSA internalization. 
Moreover, in contrast to HSA-dependent and independent 
14C-Dp44mT uptake (Fig. 5A), and 125I-HSA uptake 
(Fig. 5D), the uptake of 59Fe-125I-Tf occurred by the 
well characterized endocytic mechanism that required 
acidification [52, 69-71]. This was demonstrated by the 
inhibition of 59Fe-Tf uptake (Fig. 5C), and to a lesser 
extent 125I-Tf uptake (Fig. 5B), by lysosomotropic agents 
(Fig. 7E).
In terms of the mechanism of intracellular uptake 
of other molecules bound to HSA (e.g., fatty acids), it 
has been reported that after HSA-binding to the cell 
membrane, fatty acid-bound albumin undergoes a 
conformational change [5, 11]. This alteration then results 
in fatty acid release in the proximity of the membrane for 
cellular uptake [5, 11]. The subsequent reduced affinity of 
albumin for the cell surface then leads to its release from 
the membrane [5, 11]. Similar mechanisms of transport 
have also been proposed for albumin-bound testosterone 
and tryptophan [5, 12-14]. In an analogous way to 
Dp44mT, the low affinity of albumin for testosterone 
results in the transport of this hormone from the plasma 
for rapid release and delivery to tissues [5, 80]. Hence, 
the mechanism reported in this study for HSA-mediated 
Dp44mT uptake, shows similar characteristics to those 
described for fatty acids and testosterone.
Binding of Dp44mT to HSA had the lowest relative 
affinity relative to Bp4eT and PIH (Fig. 2A). Hence, the 
relatively low affinity of Dp44mT for HSA may facilitate 
the release of Dp44mT for uptake by passive diffusion 
(Fig. 7C). In contrast, the relatively higher affinity of 
Bp4eT and PIH may prevent this (Fig. 7A), and thus, 
this may explain the differential effects of HSA observed 
on ligand uptake demonstrated herein. Considering this, 
it is notable that the ability of HSA to inhibit Bp4eT or 
PIH uptake was irrespective of the cell-type assessed 
(Supplementary Fig. 2B-C), suggesting the inhibition 
was independent of the cell-type. In marked contrast, the 
stimulation of Dp44mT uptake by HSA was dependent on 
cell-type (Supplementary Fig. 2A), implicating the crucial 
role of the cell via the expression of HSA-binding sites in 
terms of the effect observed.
HsA Potentiates Dp44mt targeting to tumor 
cells resulting in Increased Anti-Proliferative 
and Apoptotic Activity
Significantly, HSA increased the anti-proliferative 
and apoptotic effects of Dp44mT (Fig. 6). Hence, the 
HSA-mediated increase in 14C-Dp44mT uptake and 
targeting (Fig. 3A, D, E) enhanced the anti-tumor efficacy 
of this drug. Conversely, the addition of HSA decreased 
the anti-proliferative activity of Bp4eT and PIH (Fig. 6A) 
and inhibited the ability of Bp4eT to induce apoptosis 
(Fig. 6B). This can be attributed to the HSA-induced 
inhibition of 14C-Bp4eT and 14C-PIH uptake (Fig. 3B-D), 
resulting in reduced anti-cancer efficacy of these ligands. 
These observations could be important for designing new 
therapeutics based on Dp44mT that enhance its biological 
efficacy. For instance, albumin-containing nanoparticles 
have been utilized for improving the activity of standard 
chemotherapeutics [17, 81, 82]. These agents utilize the 
enhanced permeability and retention effect and cellular 
uptake pathways of albumin to enhance drug permeation 
into tumors [17, 81-83].
Albumin nanoparticles containing the established 
chemotherapeutic, paclitaxel (marketed under the name 
Abraxane®), have been approved for the treatment of breast 
cancer, pancreatic adenocarcinoma and non-small cell lung 
cancer [84-86]. In fact, Abraxane® is less toxic and more 
effective than conventional paclitaxel [84-86]. Similarly, 
the development of albumin nanoparticles containing 
thiosemicarbazones, such as Dp44mT, may enhance the 
delivery, anti-tumor targeting, selectivity and toxicological 
profile of this agent. Other thiosemicarbazone-loaded 
nanoparticles (known as “nanochelators”) have been 
examined [87], although albumin was not utilized in their 
composition to enhance uptake. Hence, the development 
of novel albumin-containing nanoparticles represents an 
exciting therapeutic avenue. 
In conclusion, physiological levels of HSA mediate 
the enhanced cellular uptake and targeting of Dp44mT, 
resulting in increased anti-proliferative and apoptotic 
activity. The uptake of Dp44mT in the presence of HSA 
could provide therapeutic benefits by delivering greater 





HSA (≥99% purity; Cat. #A8763), BSA (≥98% 
purity; Cat. #A7906), transferrin (Tf; ≥98% purity; Cat. 
#T4382), warfarin (Cat. #A2250) and ibuprofen (Cat. 
#I4883) were purchased from Sigma-Aldrich (St. Louis, 
MO). The non-radiolabeled ligands, Dp44mT, Bp4eT and 
PIH, were synthesized and characterized by established 
methods [23, 37, 38]. The 14C-labeled chelators, 
14C-Bp4eT, 14C-Dp44mT and 14C-PIH, were synthesized 
by the Institute of Isotopes Ltd (Budapest, Hungary) and 
were purified and prepared as previously described [34, 
35]. 
Fluorescence Quenching studies 
The fluorescence spectra of HSA (2 µM) was 
measured with increasing concentrations of the chelators, 
Dp44mT, Bp4eT or PIH (0-3.67 µM), after a 2 h 
incubation at 37˚C on a LS-55 spectrofluorometer (Perkin 
Elmer Life and Analytical Sciences, Waltham, MA) with 
a 1 cm path-length quartz cell using 15 nm/6 nm slit 
widths and a thermostat bath. The excitation and emission 
wavelengths for HSA were 295 nm and 310-450 nm, 
respectively, with scanning at 5 nm increments.
circular Dichroism
Far-UV CD data were collected using a Jasco 815 
spectropolarimeter equipped with a Peltier- thermostated 
6-chamber sample holder at 20°C (JASCO, Tokyo, Japan) 
using a 1 mm path-length quartz cell. Stock solutions of 
the chelators (1 mM) were prepared in ethanol. Samples 
containing HSA (2 μM) in the presence and absence of 
the chelators, Dp44mT, Bp4eT or PIH (10 μM), or the 
chaotrope, GndCl (Sigma-Aldrich; 6 M), were prepared in 
PBS and incubated at 37˚C for 2 h prior to measurement. 
Spectra were collected at 20 nm/min over the range of 
200–250 nm, with a sensitivity of 100, step size of 1 nm, 
digital integration time of 1 s and are the average of five 
scans with buffer baseline correction and background 
subtraction. The percentage of α-helices and β-sheets was 
calculated using DichroCalc [88].
Equilibrium Dialysis studies
Equilibrium dialysis experiments were performed 
using standard methods [44]. In these studies, HSA (40 
mg/mL) was incubated with an excess of warfarin or 
ibuprofen (5 mM) or an excess of unlabeled Dp44mT, 
Bp4eT or PIH (0.5 mM) in PBS for 2 h/37oC in PBS to 
duplicate the experimental conditions utilized for uptake 
experiments with the 14C-labeled ligands (see below). The 
14C-chelators (25 µM) were then added and the samples 
were further incubated for 2 h/37oC. The solutions 
were then placed in a dialysis membrane sac with a 12 
kDa molecular weight cut-off (Sigma-Aldrich). These 
samples underwent dialysis in PBS and were allowed to 
equilibrate for 24 h/4oC on a rotating mixer. Experiments 
using the 14C-labeled ligands alone demonstrated that after 
this incubation period, an equilibrium was established 
with equal amounts of the label inside and outside of 
the dialysis sac. Then 1 mL aliquots were taken from 
the dialysate and the dialysis sac and were processed 
as previously described [34] using an oxidizer (Sample 
Oxidizer Model 307; Perkin Elmer Life and Analytical 
Sciences) to prevent quenching. The radioactivity in 
samples was measured using a Wallac 1450 MicroBeta 
TriLux β Counter (PerkinElmer) with appropriate 
calibration standards and background controls. The results 
were expressed as % of chelator released from the dialysis 
sack into the dialysate.
computational Docking studies
The 2-D structures of the HSA-binding ligands 
were built using the Schrödinger suite (Schrödinger Inc., 
New York, NY, USA). Geometry minimizations were 
performed on all ligand conformations, with all possible 
ionization states at pH 7.0 ± 2.0, using the OPLS_2005 
force field in MacroModel v9.8 and the Truncated Newton 
Conjugate Gradient. Optimizations were converged 
to a gradient RMSD below 0.05 kJ/mol, or continued 
to a maximum of 5000 iterations, at which there were 
negligible changes in RMSD gradients. Glide v5.8 and the 
extra precision scoring function were used to estimate the 
affinities of protein–ligand binding [89].
Initially, warfarin, Dp44mT, Bp4eT and PIH, were 
docked into Sudlow’s site I (warfarin site), where the 
docking grid was defined and generated based upon the 
ligand-binding domain of the crystal structure of HSA in 
complex with warfarin (Protein Data Bank (PDB) code: 
2BXD; www.rcsb.org). Similarly, the binding site for 
Sudlow’s site II (ibuprofen site) was obtained from the 
co-crystal structure of HSA with ibuprofen (PDB code: 
2BXG), where ibuprofen defined the centroid of the 
docking grid. No constraints were fixed in the active site, 
allowing the ligands to bind in all possible orientations. 
Protein preparation and refinement protocols were 
performed on the structure (Protein Preparation Wizard, 
Schrödinger). 
cell culture
The following human cell-types were obtained 
from the American Type Culture Collection (ATCC; 
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Manassas, VA), namely DMS-53 lung carcinoma cells, 
SK-N-MC neuroepithelioma cells, SK-Mel-28 melanoma 
cells, MCF-7 breast cancer cells, MRC-5 fibroblast cells, 
HepG2 hepatocellular carcinoma and the papillomavirus 
16 transformed kidney proximal tubule HK-2 cells. All 
of these cell-types, except DMS-53 lung carcinoma cells, 
were cultured as previously described [35] in minimum 
essential media (MEM; Life Technologies) at 37oC. 
The DMS-53 lung carcinoma cell line was cultured in a 
similar manner as above using Roswell Park Memorial 
Institute 1640 (RPMI 1640; Life Technologies). These 
media were supplemented with 10% (v/v) fetal calf serum 
(FCS; Sigma-Aldrich) and the following additives from 
Life Technologies: 1% (v/v) sodium pyruvate, 1% (v/v) 
100× non-essential amino acids, 100 U/mL penicillin, 
100 µg/mL streptomycin, 2 mM glutamine and 0.28 µg/
mL fungizone. Human umbilical vein endothelial cells 
(HUVECs) were kindly donated by Mr. P. Pisansarakit 
(Heart Research Institute, Sydney, Australia) and were 
cultured according to established techniques [35]. All cells 
were cultured in an atmosphere of 5% CO2/95% air.
cellular Uptake of 14c-Ligands
The cellular uptake of 14C-chelators was performed 
in accordance with previously established procedures [34, 
35]. Briefly, cells in culture dishes were incubated with 25 
µM of 14C-chelator in supplement- and FCS-free media 
in the presence and absence of HSA (5 or 40 mg/mL), 
BSA (40 mg/mL) or Tf (5 or 40 mg/mL) for 0-120 min at 
37oC. The cellular uptake of 14C-Dp44mT (0.1-150 µM) 
was also examined as a function of concentration in the 
absence or presence of HSA (40 mg/mL) at 4 or 37oC 
over a 2 h incubation. In studies examining the effect of 
proteins on 14C-chelator uptake as a function of protein 
concentration, cells were incubated in medium containing 
HSA or BSA (0-250 mg/mL) for 120 min/37oC. Upon 
completion of uptake experiments, cells were placed on 
ice and washed four times with ice-cold PBS. The cells 
were then resuspended the cells in PBS (1 mL) and 
Ultima Gold™ scintillation fluid was added (2.5 mL; 
PerkinElmer). Radioactivity was measured using the 
β-counter, as described above.
Assay Examining Internalized and Membrane-
bound 14c-Ligand Uptake by cells
In studies examining the internalized and 
membrane-bound uptake of the 14C-ligands, the general 
protease, “Pronase” (Sigma-Aldrich; Cat. #P8811) was 
used, implementing established methods [49, 52]. Briefly, 
cells were treated with 14C-chelators (25 µM), washed four 
times on ice with ice-cold PBS and then incubated on ice 
with Pronase (1 mg/mL) for 30 min/4°C. Subsequently, 
cells were removed from the plate on ice and centrifuged 
at 10,000 rpm/1 min/4°C. The supernatant obtained 
represents the Pronase-sensitive membrane-bound fraction 
and the pellet was resuspended in PBS and represents 
the Pronase-insensitive internalized compartment. 
Radioactivity in each fraction was assessed as described 
above.
14C-Dp44mT Cellular Efflux
Examination of 14C-Dp44mT release from pre-
labeled SK-N-MC cells was performed using standard 
techniques [34, 35]. Briefly, SK-N-MC cells were 
incubated in a similar manner to uptake studies and were 
pre-labeled with 14C-Dp44mT (25 μM) in the presence 
or absence of HSA (40 mg/mL) for 120 min/37oC. The 
cells were then placed on ice, the media removed and 
the cell monolayer washed four times with ice-cold PBS. 
Phenol red-free media containing HSA (40 mg/mL; 1 mL; 
37oC) was then added to each plate and the cells were re-
incubated at 37oC for up to 60 min/37oC. At the end of 
each reincubation period, the cells were placed on ice and 
the overlying media was placed into scintillation vials to 
estimate the level of extracellular 14C-chelator. Then PBS 
(1 mL) was added to the cells, which were subsequently 
removed from the plates using a plastic spatula. This 
suspension was placed into β-scintillation vials and 
represents cellular-associated 14C-chelator. Radioactivity 
was determined using a β-counter. Results were expressed 
as % of 14C-chelator released into the medium.
Western blot Analysis
Protein extraction from cells and western blot 
analysis were performed using established protocols 
[90]. The primary antibodies used were rabbit anti-
human calreticulin antibody (1:500; Cat. #2891, Cell 
Signaling, Boston, MA, USA), goat anti-human cubilin 
antibody (1:1000; Cat. #sc-23644, Santa Cruz, CA, USA), 
rabbit anti-human neonatal Fc receptor (FcRn) antibody 
(1:500; Cat. #sc-66892, Santa Cruz), mouse anti-human 
heterogeneous nuclear ribonucleoprotein (hnRNP) A2/
B1 antibody (1:1000; Cat. #9304, Cell Signaling), rabbit 
anti-human secreted protein acidic and rich in cysteine 
(SPARC) antibody (1:1000; Cat. #5240, Cell Signaling), 
rabbit anti-human cleaved poly ADP-ribose polymerase 
(PARP) antibody (1:1,000; Cat. #9541S, Cell Signaling) 
and mouse anti-human β-actin antibody (1:10,000; Cat. 
#A5316, Sigma-Aldrich). β-actin was used as a loading 
control. Enhanced Chemiluminescence (ECL) Plus™ 
Western Blotting Detection Reagent (GE Healthcare, 
Australia) was used for detection and images were 
processed using the ChemiDoc™ MP Imaging System 
(Bio-Rad, Hercules, CA). Densitometric analysis of 
western blots was performed using Quantity One software 
(Bio-Rad, Hercules, CA) and normalized implementing 
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the relative β-actin loading control.
Labeling of Human tf with 59Fe and 125I and 
Human serum Albumin with 125I 
Human Tf (Sigma-Aldrich) was labeled with 125I 
and 59Fe (Perkin Elmer Life and Analytical Sciences) 
using standard methods [50, 51]. HSA was labeled with 
125I using the chloramine-T method [91]. Non-protein 
bound 125I was removed by chromatography using PD10 
desalting columns (VWR International, Australia). 
Further desalting was conducted using Millipore Amicon 
Ultra-15 Ultrafiltration device (>30 kDa; Billerica, MA). 
Trichloroacetic acid (Sigma-Aldrich) precipitation was 
used to determine labeling and desalting efficiency, which 
was >95%. Protein concentration was measured using 
UV-visible spectrophotometer (UV-1800; Shimadzu, 
Kyoto, Japan) at 279 nm (εHSA = 0.531 g/L; [5]). 
Competition studies of the 125I-HSA with non-labeled HSA 
demonstrated the labeled protein retained its conformation.
125I-HsA cellular Uptake
Cellular uptake of 125I-HSA was performed as 
described above in “Cellular Uptake of 14C-Ligands” 
with modifications. SK-N-MC cells were incubated with 
125I-HSA (0.001-10 mg/mL) in FCS-free media in the 
presence and absence of unlabeled Dp44mT (25 µM) for 
2 h/37oC. In subsequent studies performed as a function of 
time, cells were incubated with 125I-HSA at a concentration 
of 7.5 mg/mL, as it provided appropriate levels of cellular 
labeling. The uptake of 125I-HSA was examined in the 
presence and absence of unlabeled Dp44mT, Bp4eT 
or PIH (25 µM) over 5-30 min/37oC. At the end of the 
incubation, cells were placed on ice, the medium removed 
and cells washed four times with ice-cold PBS. Cells were 
then incubated with Pronase (1 mg/mL) for 30 min/4oC to 
separate the membrane-bound and internalized 125I-HSA 
fractions. Radioactivity was measured on a γ-counter 
(Wallac Wizard 3, Perkin Elmer Life and Analytical 
Sciences).
Non-Linear regression Analysis of Ligand 
binding to cells
Non-linear regression analysis was performed in 
studies examining cellular 14C-ligand or 125I-labeled HSA 
uptake as a function of concentration using GraphPad 
Prism 5.0 Software (San Diego, CA) to measure the 
maximum number of binding sites (Bmax) and the 
equilibrium dissociation constant (Kd).
Effect of Metabolic and Endocytosis Inhibitors, 
Temperature, Lysosomotropic Agents and Excess 
Ligand on the cellular Uptake of 14c-Dp44mt, 
125I-HsA and 59Fe-125I-tf
The cellular uptake of 14C-Dp44mT, 125I-HSA or 
59Fe-125I-Tf in the presence or absence of metabolic and 
endocytosis inhibitors, lysosomotropic agents or at 4oC, 
was performed as described above in the “Cellular Uptake 
of 14C-Ligands” and “125I-HSA Cellular Uptake” sections 
with modifications. SK-N-MC cells were pre-incubated 
for 30 min/37oC with: (1) FCS-free media; (2) FCS- and 
glucose (Glu)-free media (-Glu); (3) FCS- and Glu-free 
media containing the known metabolic inhibitors (Sigma-
Aldrich), sodium azide (NaN3; 30 mM) or sodium cyanide 
(NaCN; 5 mM) used previously [34, 35]; (4) FCS-free 
media at 4˚C; (5) FCS-free media containing the well 
characterized endocytosis inhibitor, phenylglyoxal (PGO; 
5 mM; Sigma-Aldrich) [64-67]; or (6) FCS-free media 
containing the lysosomotropic agents (Sigma-Aldrich), 
ammonium chloride (NH4Cl; 15 mM) or methylamine 
(MeNH2; 15 mM) [52, 65, 68]; or (7) a 100-fold excess of 
unlabeled Fe-Tf or HSA (75 µM) at 37˚C unless otherwise 
stated. 
The media were then removed and the cells 
subsequently incubated under the seven preincubation 
conditions listed above in the presence of 14C-Dp44mT 
(25 µM) with or without HSA (40 mg/mL), 125I-HSA 
(0.75 µM) or 59Fe-125I-Tf (0.75 µM) for 1 h at 37oC unless 
otherwise stated. Radioactivity in the 14C-Dp44mT-
containing samples was then measured using the β-counter 
above. The intracellular levels of 125I-HSA, 59Fe or 125I-
Tf were examined by measuring the radioactivity of 
the Pronase-insensitive (internalized) fraction using the 
γ-counter, as described above.
cell Growth Inhibition Assay by Direct cell 
counts
SK-N-MC cells were seeded in 24-well plates at 
a density of 7.5 x 104 cells/well in 500 µL of complete 
culture medium and incubated overnight at 37oC. After this 
incubation, cells were treated for 24 h/37oC with Dp44mT 
(30, 60 or 120 µM), Bp4eT (30, 60 or 120 µM), PIH (125, 
250 or 500 µM) or the vehicle alone (control) in complete 
MEM containing diferric Tf (1.2 µM; Sigma-Aldrich) in 
the presence or absence of HSA (40 mg/mL). Cells were 
then harvested using PBS/EDTA, resuspended and stained 
using Trypan blue (0.4%; Sigma-Aldrich). Cell counts and 
viability were assessed by direct manual counting using a 
hemocytometer. Results were expressed as a percentage 
of the control and the concentration required to inhibit 
growth by 50% (IC50) was calculated.
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statistical Analysis
Data was expressed as mean ± S.E.M of at least 
3 experiments. Statistical analysis was performed using 
Student’s t-test.
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